BiotechTube

SHR-1703 + SHR-1703 Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma With Eosinophilic Phenotype

Conditions

Asthma With Eosinophilic Phenotype

Trial Timeline

Dec 22, 2022 → Sep 12, 2024

NCT ID
NCT05522439

About SHR-1703 + SHR-1703 Placebo

SHR-1703 + SHR-1703 Placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Asthma With Eosinophilic Phenotype. The current trial status is completed. This product is registered under clinical trial identifier NCT05522439. Target conditions include Asthma With Eosinophilic Phenotype.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05522439Phase 2Completed

Competing Products

20 competing products in Asthma With Eosinophilic Phenotype

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
77
DuleraMerckApproved
85
BriquilimabJasper TherapeuticsPhase 1
25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
52
RoflumilastAstraZenecaPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
52
Regadenoson + PlaceboAstellas PharmaApproved
85
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
77
rabeprazoleEisaiPhase 3
77
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
Placebo + BrodalumabKyowa KirinPhase 2
52
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
52
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85